Wall Street is going back to cautious as strong labour market data and status-quo-reaffirming remarks from Fed’s Chair Jerome Powell push back the interest rate cut expectations. Nasdaq takes the largest hit (-0.8%), followed by S&P 500 (-0.2%) and Russell 2000 (-0.1%). Dow Jones is the only exception today (+0.5%), supported mainly by healthcare and materials sectors.
Today’s batch of macroeconomic data supports the Fed’s wait-and-see approach. Although the ISM report for manufacturing showed a slower-than-expected contraction of the sector, the price pressures persist. This, compared with stronger hiring appetite (as indicated by the stronger-than-expected JOLTS report), weighs on recently dovish signals from Fed representatives, simultaneously fueling yields on US treasuries.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile app
Volatility in DJIA sectors. Source: Bloomberg Finance LP
US100 (H1)
Nasdaq futures lost steam after closing the quarter at new all-time highs. The contract has now fallen well below its 24-hour exponential moving average, with buyers failing to hold the support level around 22,760. Tesla led the decline, dropping 6% and becoming the biggest drag on the index. Key semiconductor stocks also weighed heavily on performance, with Nvidia down 2.9%, Broadcom falling 3%, and AMD sliding 3.6%.
Source: xStation5
Company news:
-
AMC shares fell 7.7% after announcing a debt restructuring deal with key creditors. The agreement includes $223 million in new financing, a $143 million debt-for-equity swap, and potential total equitization of up to $337 million. It also settles litigation over 2029 notes and helps refinance debt maturing in 2026, easing near-term financial pressure.
-
Insulet, Dexcom, and other diabetes device makers fell after U.S. regulators proposed shifting to a monthly rental payment model for insulin pumps and CGM systems, replacing the current rent-to-own structure. The CMS also introduced a competitive bidding plan. Analysts see limited immediate financial risk but expect increased price pressure and competitive switching, especially for Tandem and Beta Bionics.
-
Tesla shares are down 6% as tensions reignited between Donald Trump and Elon Musk. Trump threatened to revoke subsidies for Musk’s companies and hinted at reviewing his immigration status, after Musk criticized the president’s tax bill. The renewed feud follows GOP plans to phase out the $7,500 EV tax credit, a key benefit for Tesla.
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
